权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SIGNIFICANCE OF NEUROPEPTIDE Y IN EARLY DIAGNOSIS AND AS A PROGNOSTIC FACTOR OF NEUROBLASTOMA

神经肽 Y 在早期诊断中的意义以及作为神经母细胞瘤预后因素的意义

基本信息

批准号：
03670577
负责人：
HAYASHI Yutaka
金额：
$ 1.34万
依托单位：
TOHOKU UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1991
资助国家：
日本
起止时间：
1991 至 1993
项目状态：
已结题

项目摘要

Plasma neuropeptide Y(NPY) concentrations were detected in 44 cases with neuroblastoma (NB) and 48 cases without NB.Sensitivity and specificity of NPY on the diagnosis of NB were 84% and 92%, respectively. NPYs in NB cases were significantly lower in cases of younger than 1-year-old than in older cases, in granglioneuroma than in neuroblastoma, in favorable histology (FH) than in unfavorable histology (UH), in cases detected by mass screening than in mass screening negative cases, in early staged cases than in advanced cases, respectively. NPYs did not correlated with any other tumor markers including VMA and HVA in urine, plasma NSE, LDH and ferritin. NB cases were divided by the plasma NPY concentrations (Group 1 : < 1,000 pg/ml, Group 2 : 1,000-3,000 pg/ml, Group 3 : > 3,000 pg/ml) to analyze the relationship between NPYs and prognosis. Survival rate of Group 1 was significantly better than those of Group 2 and 3. All of the patients of Group 1 survived without any evidence of disease. The prognosis of FH cases in Group 1 was excellent but the prognoses of FH in Group 2 and 3 were not good. Four patients with amplified N-myc were classified in Group 2 or 3.Urinary NPY was measured and NPY like immunoreactivity from 40 to 200 pg/ml in concentration was detected. It was found that major component of NPY in urine shifted to low molecular wieght area. It was considered NPY to be metabolized at the urinary system and to be possible to measure urinary NPY concentrations.

检测44例神经母细胞瘤（NB）和48例非NB患者血浆神经肽Y（NPY）浓度，其诊断NB的敏感性和特异性分别为84%和92%。1岁以下NB患者的NPYs显著低于1岁以上患者，神经节细胞瘤显著低于神经母细胞瘤，组织学良好者（FH）显著低于组织学不良者（UH），筛查阳性组显著低于筛查阴性组，早期组显著低于晚期组。NPY与尿VMA、HVA、血浆NSE、LDH、铁蛋白等肿瘤标志物均无相关性。根据血浆NPY浓度将NB患者分为3组（第1组：< 1,000 pg/ml，第2组：1,000-3,000 pg/ml，第3组：> 3,000 pg/ml），分析NPY与预后的关系。第1组的生存率明显优于第2组和第3组。第1组的所有患者均存活，无任何疾病证据。第1组FH患者预后良好，而第2、3组FH患者预后不佳。4例N-myc扩增者分为第2组和第3组。检测尿NPY，发现尿中NPY样免疫反应物浓度为40 ~ 200 pg/ml。发现尿中NPY主要成分向低分子量区转移。认为NPY在泌尿系统代谢，可以测定尿中NPY浓度。